Molecular network profiling of U373MG human glioblastoma cells following induction of apoptosis by novel marine-derived anti-cancer 1,2,3,4-tetrahydroisoquinoline alkaloids

Cancer Cell International

Volumn 12, Issue , 2012, Pages

  Tabunoki, Hiroko ^a   Saito, Naoki ^a   Suwanborirux, Khanit ^b   Charupant, Kornvika ^c   Satoh, Jun Ichi ^a  

^a MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^b CHULALONGKORN UNIVERSITY   (Thailand)

^c MINISTRY OF PUBLIC HEALTH   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALOID; ANTINEOPLASTIC AGENT; ECTEINASCIDIN 770; EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCOGEN SYNTHASE KINASE 3; RENIERAMYCIN E; RENIERAMYCIN M; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BIOINFORMATICS; BRAIN DEVELOPMENT; CANCER CELL CULTURE; CELL MOTION; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG ISOLATION; DRUG STRUCTURE; DRUG SYNTHESIS; GENE EXPRESSION PROFILING; GLIOBLASTOMA; HUMAN; HUMAN CELL; IC 50; UPREGULATION;

EID: 84859498749     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-12-14     Document Type: Article

References (28)

1. Ohgaki H, Kleihues P. Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci 2009, 100:2235-2241. 10.1111/j.1349-7006.2009.01308.x, 19737147.
2. Li B, Yuan M, Kim IA, Chang CM, Bernhard EJ, Shu HK. Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin. Oncogene 2004, 23:4594-4602. 10.1038/sj.onc.1207602, 15077177.
3. Clarke J, Butowski N, Chang S. Recent advances in therapy for glioblastoma. Arch Neurol 2010, 67:279-283. 10.1001/archneurol.2010.5, 20212224.
4. Satoh J, Tabunoki H, Arima K. Molecular network analysis suggests aberrant CREB-mediated gene regulation in the Alzheimer disease hippocampus. Dis Markers 2009, 27:239-252.
5. Albert R, Jeong H, Barabasi AL. Error and attack tolerance of complex networks. Nature 2000, 406:378-382. 10.1038/35019019, 10935628.
6. Garcia-Carbonero R, Supko JG, Manola J, Seiden MV, Harmon D, Ryan DP, Quigley MT, Merriam P, Canniff J, Goss G, Matulonis U, Maki RG, Lopez T, Puchalski TA, Sancho MA, Gomez J, Guzman C, Jimeno J, Demetri GD. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004, 22:1480-1490. 10.1200/JCO.2004.02.098, 15084621.
7. Gajate C, An F, Mollinedo F. Differential cytostatic and apoptotic effects of ecteinascidin-743 in cancer cells. Transcription-dependent cell cycle arrest and transcription-independent JNK and mitochondrial mediated apoptosis. J Biol Chem 2002, 277:41580-41589.
8. Martínez N, Sánchez-Beato M, Carnero A, Moneo V, Tercero JC, Fernández I, Navarrete M, Jimeno J, Piris MA. Transcriptional signature of ecteinascidin 743 (yondelis, trabectedin) in human sarcoma cells explanted from chemo-naive patients. Mol Cancer Ther 2005, 4:814-823. 10.1158/1535-7163.MCT-04-0316, 15897246.
9. D'Incalci M, Galmarini CM. A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther 2010, 9:2157-2163. 10.1158/1535-7163.MCT-10-0263, 20647340.
10. Suwanborirux K, Charupant K, Amnuoypol S, Pummangura S, Kubo A, Saito N. Ecteinascidins 770 and 786 from the Thai tunicate Ecteinascidia thurstoni. J Nat Prod 2002, 65:935-937. 10.1021/np010485k, 12088444.
11. Saktrakulkla P, Toriumi S, Tsujimoto M, Patarapanich C, Suwanborirux K, Saito N. Chemistry of ecteinascidins. Part 3: preparation of 2'-N-acyl derivatives of ecteinascidin 770 and evaluation of cytotoxicity. Bioorg Med Chem 2011, 19:4421-4436. 10.1016/j.bmc.2011.06.047, 21752654.
12. Suwanborirux K, Amnuoypol S, Plubrukarn A, Pummangura S, Kubo A, Tanaka C, Saito N. Chemistry of renieramycins. Part 3: isolation and structure of stabilized renieramycin type derivatives possessing antitumor activity from Thai sponge Xestospongia species, pretreated with potassium cyanide. J Nat Prod 2003, 66:1441-1446. 10.1021/np030262p, 14640515.
13. Charupant K, Suwanborirux K, Daikuhara N, Yokoya M, Ushijima-Sugano R, Kawai T, Owa T, Saito N. Microarray-based transcriptional profiling of renieramycin M and jorunnamycin C, isolated from Thai marine organisms. Mar Drugs 2009, 7:483-494. 10.3390/md7040483, 2810219, 20098592.
14. Halim H, Chunhacha P, Suwanborirux K, Chanvorachote P. Anticancer and antimetastatic activities of renieramycin M, a marine tetrahydroisoquinoline alkaloid, in human non-small cell lung cancer cells. Anticancer Res 2011, 31:193-202.
15. Charupant K, Daikuhara N, Saito E, Amnuoypol S, Suwanborirux K, Owa T, Saito N. Chemistry of renieramycins. Part 8: synthesis and cytotoxicity evaluation of renieramycin M-jorunnamycin A analogues. Bioorg Med Chem 2009, 17:4548-4558. 10.1016/j.bmc.2009.05.009, 19457672.
16. da Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009, 4:44-57.
17. Draghici S, Khatri P, Tarca AL, Amin K, Done A, Voichita C, Georgescu C, Romero R. A systems biology approach for pathway level analysis. Genome Res 2007, 17:1537-1545. 10.1101/gr.6202607, 1987343, 17785539.
18. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812. 10.1126/science.1164382, 2820389, 18772396.
19. Mure H, Matsuzaki K, Kitazato KT, Mizobuchi Y, Kuwayama K, Kageji T, Nagahiro S. Akt2 and Akt3 play a pivotal role in malignant gliomas. Neuro Oncol 2010, 12:221-232. 10.1093/neuonc/nop026, 2940586, 20167810.
20. Endersby R, Zhu X, Hay N, Ellison DW, Baker SJ. Nonredundant functions for Akt isoforms in astrocyte growth and gliomagenesis in an orthotopic transplantation model. Cancer Res 2011, 71:4106-4116. 10.1158/0008-5472.CAN-10-3597, 3118569, 21507933.
21. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 2003, 116:1175-1186. 10.1242/jcs.00384, 3006448, 12615961.
22. Kotliarova S, Pastorino S, Kovell LC, Kotliarov Y, Song H, Zhang W, Bailey R, Maric D, Zenklusen JC, Lee J, Fine HA. Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kB, and glucose regulation. Cancer Res 2008, 68:6643-6651. 10.1158/0008-5472.CAN-08-0850, 2585745, 18701488.
23. Korur S, Huber RM, Sivasankaran B, Petrich M, Morin P, Hemmings BA, Merlo A, Lino MM. GSK3β regulates differentiation and growth arrest in glioblastoma. PLoS One 2009, 4:7443.
24. Swiss VA, Casaccia P. Cell-context specific role of the E2F/Rb pathway in development and disease. Glia 2010, 58:377-390. 2882865, 19795505.
25. Yamashita Y, Kasugai I, Sato M, Tanuma N, Sato I, Nomura M, Yamashita K, Sonoda Y, Kumabe T, Tominaga T, Katakura R, Shima H. CDC25A mRNA levels significantly correlate with Ki-67 expression in human glioma samples. J Neurooncol 2010, 100:43-49. 10.1007/s11060-010-0147-3, 20217459.
26. Chou ST, Yen YC, Lee CM, Chen MS. Pro-apoptotic role of Cdc25A: activation of cyclin B1/Cdc2 by the Cdc25A C-terminal domain. J Biol Chem 2010, 285:17833-17845. 10.1074/jbc.M109.078386, 2878547, 20368335.
27. Jarzynka MJ, Hu B, Hui KM, Bar-Joseph I, Gu W, Hirose T, Haney LB, Ravichandran KS, Nishikawa R, Cheng SY. ELMO1 and Dock180, a bipartite Rac1 guanine nucleotide exchange factor, promote human glioma cell invasion. Cancer Res 2007, 67:7203-7211. 10.1158/0008-5472.CAN-07-0473, 2867339, 17671188.
28. Lan Y, Kingsley PD, Cho ES, Jiang R. Osr2, a new mouse gene related to Drosophila odd-skipped, exhibits dynamic expression patterns during craniofacial, limb, and kidney development. Mech Dev 2001, 107:175-179. 10.1016/S0925-4773(01)00457-9, 11520675.